Recurrent Urethral Cancer Recruiting Phase 2 Trials for Afatinib (DB08916)

Also known as: Urethral cancer recurrent / Urethra cancer recurrent

IndicationStatusPhase
DBCOND0028817 (Recurrent Urethral Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02122172Afatinib in Advanced Refractory Urothelial CancerTreatment